SN. Stock Overview
Develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 4/6 |
Dividends | 3/6 |
Smith & Nephew plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£11.80 |
52 Week High | UK£12.45 |
52 Week Low | UK£8.87 |
Beta | 0.60 |
11 Month Change | 11.06% |
3 Month Change | 17.77% |
1 Year Change | 5.41% |
33 Year Change | -14.53% |
5 Year Change | -37.64% |
Change since IPO | 5,850.82% |
Recent News & Updates
Recent updates
Statutory Profit Doesn't Reflect How Good Smith & Nephew's (LON:SN.) Earnings Are
Aug 08Smith & Nephew (LON:SN.) Will Be Hoping To Turn Its Returns On Capital Around
Jun 16Smith & Nephew plc (LON:SN.) Not Flying Under The Radar
Apr 16Is Smith & Nephew plc (LON:SN.) Trading At A 30% Discount?
Mar 16Capital Allocation Trends At Smith & Nephew (LON:SN.) Aren't Ideal
Feb 21Is Smith & Nephew plc (LON:SN.) Trading At A 36% Discount?
Dec 15Is Smith & Nephew (LON:SN.) Using Too Much Debt?
Nov 30Smith & Nephew (LON:SN.) Could Be Struggling To Allocate Capital
Oct 29Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 65% Above Its Share Price
Sep 11Smith & Nephew (LON:SN.) Has A Pretty Healthy Balance Sheet
Aug 19Investors Could Be Concerned With Smith & Nephew's (LON:SN.) Returns On Capital
Jul 17Smith & Nephew plc (LON:SN.) Shares Could Be 22% Below Their Intrinsic Value Estimate
Jun 11Smith & Nephew (LON:SN.) Seems To Use Debt Quite Sensibly
May 09Smith & Nephew (LON:SN.) Will Want To Turn Around Its Return Trends
Apr 09Calculating The Intrinsic Value Of Smith & Nephew plc (LON:SN.)
Feb 09We Think Smith & Nephew (LON:SN.) Can Stay On Top Of Its Debt
Nov 21Returns On Capital Signal Tricky Times Ahead For Smith & Nephew (LON:SN.)
Nov 08Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 99% Above Its Share Price
Oct 26These 4 Measures Indicate That Smith & Nephew (LON:SN.) Is Using Debt Reasonably Well
Aug 11There Are Reasons To Feel Uneasy About Smith & Nephew's (LON:SN.) Returns On Capital
Jul 28Smith & Nephew plc's (LON:SN.) Intrinsic Value Is Potentially 58% Above Its Share Price
Jun 26Some Investors May Be Worried About Smith & Nephew's (LON:SN.) Returns On Capital
Apr 29These 4 Measures Indicate That Smith & Nephew (LON:SN.) Is Using Debt Safely
Mar 26Shareholder Returns
SN. | GB Medical Equipment | GB Market | |
---|---|---|---|
7D | 5.0% | 2.3% | -2.7% |
1Y | 5.4% | 1.8% | 5.7% |
Return vs Industry: SN. exceeded the UK Medical Equipment industry which returned 0.5% over the past year.
Return vs Market: SN. matched the UK Market which returned 4.9% over the past year.
Price Volatility
SN. volatility | |
---|---|
SN. Average Weekly Movement | 3.5% |
Medical Equipment Industry Average Movement | 5.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 10.0% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: SN. has not had significant price volatility in the past 3 months.
Volatility Over Time: SN.'s weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1856 | 18,000 | Deepak Nath | www.smith-nephew.com |
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Smith & Nephew plc Fundamentals Summary
SN. fundamental statistics | |
---|---|
Market cap | UK£10.28b |
Earnings (TTM) | UK£240.36m |
Revenue (TTM) | UK£4.45b |
42.8x
P/E Ratio2.3x
P/S RatioIs SN. overvalued?
See Fair Value and valuation analysisEarnings & Revenue
SN. income statement (TTM) | |
---|---|
Revenue | US$5.64b |
Cost of Revenue | US$1.67b |
Gross Profit | US$3.97b |
Other Expenses | US$3.66b |
Earnings | US$305.00m |
Last Reported Earnings
Jun 29, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.35 |
Gross Margin | 70.33% |
Net Profit Margin | 5.41% |
Debt/Equity Ratio | 66.7% |
How did SN. perform over the long term?
See historical performance and comparisonDividends
2.5%
Current Dividend Yield107%
Payout RatioDoes SN. pay a reliable dividends?
See SN. dividend history and benchmarksSmith & Nephew dividend dates | |
---|---|
Ex Dividend Date | Oct 03 2024 |
Dividend Pay Date | Nov 08 2024 |
Days until Ex dividend | 55 days |
Days until Dividend pay date | 91 days |
Does SN. pay a reliable dividends?
See SN. dividend history and benchmarks